Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
NCT ID: NCT00084071
Last Updated: 2020-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2136 participants
INTERVENTIONAL
2004-05-31
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tifacogin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pneumonia of sufficient severity to require ICU admission and management
Exclusion Criteria
* Weight over 150 kg
* Patients at increased risk of bleeding
* Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa
* Treatment with heparin or anticipated need for heparin
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis
Role: STUDY_DIRECTOR
Novartis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile, Alabama, United States
Loma Linda, California, United States
Los Angeles, California, United States
Orange, California, United States
Sacramento, California, United States
San Diego, California, United States
San Jose, California, United States
Denver, Colorado, United States
Farmington, Connecticut, United States
New Haven, Connecticut, United States
Newark, Delaware, United States
Bay Pines, Florida, United States
Clearwater, Florida, United States
Fort Lauderdale, Florida, United States
Jacksonville, Florida, United States
Atlanta, Georgia, United States
Conyers, Georgia, United States
Decatur, Georgia, United States
Chicago, Illinois, United States
Oak Park, Illinois, United States
Muncie, Indiana, United States
New Albany, Indiana, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Cumberland, Maryland, United States
Detroit, Michigan, United States
Southfield, Michigan, United States
St Louis, Missouri, United States
Butte, Montana, United States
Reno, Nevada, United States
Buffalo, New York, United States
Johnson City, New York, United States
Greensboro, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Toledo, Ohio, United States
Oklahoma City, Oklahoma, United States
Allentown, Pennsylvania, United States
Pawtucket, Rhode Island, United States
Providence, Rhode Island, United States
Spartanburg, South Carolina, United States
Knoxville, Tennessee, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Tyler, Texas, United States
Salt Lake City, Utah, United States
Norfolk, Virginia, United States
Winchester, Virginia, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Mar del Plata, Buenos Aires, Argentina
Tandil, Buenos Aires, Argentina
Tres de Febrero, Buenos Aires, Argentina
Capital Federal, , Argentina
Garran, Australian Capital Territory, Australia
Camperdown, New South Wales, Australia
Kingswood, New South Wales, Australia
Cairns, Queensland, Australia
Nambour, Queensland, Australia
Southport, Queensland, Australia
Woodville, South Australia, Australia
Hobart, Tasmania, Australia
Launceston, Tasmania, Australia
Box Hill, Victoria, Australia
Footscray, Victoria, Australia
Heidelburg, Victoria, Australia
Parkville, Victoria, Australia
Nedlands, Western Australia, Australia
Perth, Western Australia, Australia
Brussels, Jette, Belgium
Bouge, , Belgium
Braine-l'Alleud, , Belgium
Brussels, , Belgium
Ghent, , Belgium
Liège, , Belgium
Mons, , Belgium
Ottignies, , Belgium
Seraing, , Belgium
Yvoir, , Belgium
Fortaleza, Ceará, Brazil
Belgium
Salvador, Estado de Bahia, Brazil
Salvador, Estado de Bahia, Brazil
Curitiba, Paraná, Brazil
Recife, Pernambuco, Brazil
Pelotas, Rio Grande do Sul, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
Florianópolis, Santa Catarina, Brazil
Campinas, São Paulo, Brazil
São José do Rio Preto, São Paulo, Brazil
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
New Westminster, British Columbia, Canada
Surrey, British Columbia, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Winnipeg, Manitoba, Canada
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Greenfield Park, Quebec, Canada
Montreal, Quebec, Canada
Santiago, , Chile
Temuco, , Chile
Argenteuil, , France
Belfort, , France
Besançon, , France
La Roche Sur Yoon, , France
Limoges, , France
Paris, , France
Pierre-Bénite, , France
Saint-Michel, , France
Tours, , France
Lübeck, , Germany
München, , Germany
Regensburg, , Germany
George Town, , Malaysia
Johor Bahru, , Malaysia
Kota Bharu Kelantan, , Malaysia
Kuala Lumpar, , Malaysia
Kuala Selangor, , Malaysia
's-Hertogenbosch, , Netherlands
Rotterdam, , Netherlands
Utrecht, , Netherlands
Grafton, Auckland, New Zealand
Otahuhu, Auckland, New Zealand
Christchurch, , New Zealand
Hastings, , New Zealand
Lima, , Peru
Singapore, , Singapore
KwaKhangela, Durban, South Africa
Parktown, Johannesburg, South Africa
Bloemfontein, , South Africa
Centurion, , South Africa
Kimberley, , South Africa
Parktown West, , South Africa
Wŏnju, Gangwon-do, South Korea
Namdong-gu, Incheon, South Korea
Gyeonggi-do, , South Korea
Gyunggi, , South Korea
Seoul, , South Korea
Suwon, , South Korea
Sabadell, Barcelona, Spain
Madrid, , Spain
Palma de Mallorca, , Spain
Santiago de Compostela, , Spain
Glasgow, , United Kingdom
Livingston, , United Kingdom
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, Xie F, Poole L, Wunderink RG. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care. 2009;13(2):R36. doi: 10.1186/cc7747. Epub 2009 Mar 15.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CTFP561A2308 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTFP561A2308
Identifier Type: -
Identifier Source: org_study_id